Hanneke Schuitemaker Headshot
Report a problem with this profile
[email protected]

Hanneke Schuitemaker    

Virologist, Global Head of Viral Vaccine Discovery & Translational Medicine at Janssen Pharmaceuticals

Hanneke Schuitemaker is the Global Head of Viral Vaccine Discovery and Translational Medicine and the Disease Area Stronghold Leader for Viral Vaccines in Janssen Vaccines and Prevention. In addition, she has been a Professor in Virology at the Amsterdam University Medical Center since 2004.

Hanneke worked for 20+ years in academia on the pathogenesis of HIV infection and co-authored close to 300 peer reviewed scientific publications. In her current position, she is responsible for the port-folio of viral vaccine programs. Most advanced programs in that port-folio are prophylactic and/or therapeutic vaccine candidates for HIV, RSV, Multivalent filo, Ebola, sIPV, Zika and HPV.

During the COVID-19 pandemic Janssen looked to develop a COVID-19 vaccine. Their approach started with a single viral genome, which was being tested as of March 2020.The US regulator FDA approved the Johnson & Johnson Covid-19 vaccine for use on February 27, 2021. Approval by the European Medicines Agency was given on March 11.


She's a Scientist with One of the World's Most Important Jobs: Creating a Potential COVID-19 Vaccine
Imagine being a researcher who is staring down not only a highly infectious virus, but one that's caused the first global pandemic in more than 100 years. Meet Johnson & Johnson's Hanneke Schuitemaker, Ph.D.

Related Speakers View all

More like Hanneke